Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Quantitative Cell-Based Bioassays to Advance Immunotherapy Programs Targeting Immune Checkpoint Receptors

Grailer, J. et al., Promega Corporation

aacr-2020-poster-immune-checkpoint-bioassays-944

AACR 2020 Abstract #944

A major challenge in the development of antibody-based biologic drugs is access to quantitative and reproducible functional bioassays. In contrast to the cumbersome, variable methods currently used that rely on primary cells, we have developed a portfolio of functional cell-based reporter bioassays to quantitatively measure the potency of biologic drugs designed to target immune checkpoint receptors including co-inhibitory (e.g., PD-1, CTLA-4, LAG-3, SIRPα) and co-stimulatory (e.g., 4-1BB, GITR, ICOS) receptors. These bioassays consist of stable cell lines that express luciferase under the precise control of receptor-mediated intracellular signals. Here we describe the application of these MOA-based bioassays for biologics drug discovery, development, potency and stability studies. 

Get This Poster PDF

 

Upon submitting this form, you will be redirected to the poster PDF. If you have requested additional posters, a Promega representative will send those to you by e-mail within 5 business days.